NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

先天性水皰症照護·治療的全球市場:未來預測 (2021年∼2026年)

Epidermolysis Bullosa Care and Treatment market - Forecasts from 2021 to 2026

出版商 Knowledge Sourcing Intelligence 商品編碼 1013735
出版日期 內容資訊 英文 109 Pages
商品交期: 最快1-2個工作天內
價格
先天性水皰症照護·治療的全球市場:未來預測 (2021年∼2026年) Epidermolysis Bullosa Care and Treatment market - Forecasts from 2021 to 2026
出版日期: 2021年04月07日內容資訊: 英文 109 Pages
簡介

全球先天性水皰症 (EB) 轉動照護·治療的市場規模在2019年估算為14億5376萬1000美元,到2026年達到21億915萬美元。在預測期間內預計將以5.46%的年複合成長率增長。目前市場上沒有針對 EB 的治療方法,通常會注意疼痛管理、傷口護理、營養支持、感染預防和並發症的治療/預防。與此同時,世界各地的主要製藥公司正在開發和開展多種 EB 治療的臨床試驗。

本報告提供全球先天性水皰症照護·治療的市場相關分析,提供市場基本結構和主要的促進·阻礙因素,整體市場規模趨勢預測,治療的各類型·各地區的詳細趨勢,競爭情形 (策略展開情形,競爭力的評估等),主要企業簡介等調查。

目錄

第1章 簡介

第2章 分析方法

第3章 摘要整理

第4章 市場動態

  • 市場促進因素
  • 市場阻礙因素
  • 波特的五力分析
  • 產業的價值鏈分析

第5章 先天性水皰症照護·治療市場:治療類別分析

  • 簡介
  • 先天性水皰症的照護
  • 藥物
  • 外科的治療
  • 其他

第6章 先天性水皰症照護·治療市場:各地區的分析

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 其他
  • 中東·非洲
    • 沙烏地阿拉伯
    • 南非
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 泰國
    • 台灣
    • 印尼
    • 其他

第7章 競爭環境與分析

  • 主要企業·策略分析
  • 新興企業和市場收益性
  • 企業合併·收購 (M&A),契約,事業合作
  • 各供應商的競爭力矩陣

第8章 企業簡介

  • Amryt Pharma PLC
  • Abeona Therapeutics Inc.
  • Ember Therapeutics
  • TWi Pharmaceuticals Inc.
  • Amicus Therapeutics
  • InMed Pharmaceuticals Inc.
  • RegeneRx Biopharmaceuticals Inc.
  • Shionogi
  • Castle Creek Pharmaceuticals
  • Onconova Therapeutics
目錄

The global Epidermolysis Bullosa care and treatment market is expected to grow at a compound annual growth rate of 5.46% over the forecast period to reach a market size of US2,109.150 million in 2026, from US$1,453.761 million in 2019. Epidermolysis Bullosa (EB) is known as a rare and infrequent medical condition that results in mucous membranes and easy blistering of the skin. The disease is due to the mutation of at least one in the sixteen different genes. There has not been a cure for this rare condition. Management usually involves pain control, wound care, nutritional support, controlling infections, and treatment or prevention of complications. Major companies have been developing novel and solutions for the treatment of this rare problem. Government funding and support, worldwide, have been imperative for the prevention and treatment of this rare medical condition. In December 2018, Fibrocell Science Inc, which has now been acquired by Castle Creek Pharmaceutical, had received US$900,000 from Epidermolysis Bullosa Research Foundation and EB Research Partnership to advance the company's FCX-007 gene therapy for the treatment of EB. Epidermolysis Bullosa is termed a genetic disease. There are three types of EB, known as EB simplex, Dystrophic EB, and Junctional EB.

Key Developments.

EB has been becoming one of the major medical conditions, worldwide. Around 500,000 people are being affected by EB, globally, according to several official sources. According to the data given by the National Epidermolysis Bullosa Registry, an estimated number of twenty newborns per one million live births in the United States has Epidermolysis Bullosa. There has not been an exact number of people with EB, but several estimates and official projections showed that around 25,000-50,000 people in the United States, have Epidermolysis Bullosa. Moreover, according to several official publications, the prevalence rate had increased in the past twenty years. These trends are expected to have a positive impact on the market, as the investment in the treatment of EB Is expected to surge in the coming years. In May 2021, Elon-gate, a cryptocurrency token for charitable giving, announced that it had donated US$150,000 to the EB research partnership (EBRP), the biggest worldwide non-profit funding research to discover and provide cures and treatments for EB. The EBRP funds research and development projects that study groundbreaking technologies, such as exon skipping, gene editing, and stem cell therapies, to cure EB by the year 2030. Other companies and institutions have also been making significant developments in the market. For instance, in April 2021, Onconova Therapeutics Inc., a biopharmaceutical firm focused on discovering and developing new and advanced products for patients with cancer, announced that their first and novel patients had been dosed in the company's Phase 2 study to learn and assess the safety and efficacy of rigosertib in patients with recessive dystrophic epidermolysis bullosa, advanced squamous cell carcinoma. The patient was dosed at EB House Austria, which has been a center for EB at the University Hospital Salzburg. This development is expected to have a positive impact on the market, during the forecast period. Various studies by the major and reputed institutions, private firms, and hospitals are having a substantial impact on the market. The development of novel, innovative and advanced solutions for the cure and treatment of EB is likely to surge in the coming years. With the COVID-19 pandemic affecting the global population, there has been a serious discussion to increase the investment in the treatment of rare genetic diseases. In October 2020, it was announced that a phase 2 trial of PTR-01, which has been a treatment for recessive dystrophic epidermolysis bullosa, had been dosed in its novel patient. The study had been taking place at Children's Hospital Colorado and Stanford University. These developments are expected to have a positive impact on the market, during the forecast period.

Competitive Analysis.

Major companies have been making significant developments in the market. The increase in the enrollment of patients for company's and medical institutions trials are likely to have a positive impact on the EB care and treatment market. For instance, in August 2019, RegeneRx Biopharmaceuticals Inc., a drug development company focused on tissue repair, protection, and regeneration, announced that their first and novel patient enrolled in phase 2 trial of epidermolysis bullosa had reacted positively to the company's novel and advanced drug candidate called as RGN-137. The trial had been sponsored by Lenus Therapeutics LLC, a joint venture owned by Yuang DNU Co. Ltd., and GtreeBNT, to develop RGN-137 in Canada, the USA, Japan, Korea, and Europe. The company has been making significant developments in the market, in the past few years. Other players are also making a substantial impact in the EB care and treatment market. For instance, in September 2020, InMed Pharmaceuticals, a clinical-stage pharmaceutical firm, had announced that all of their patients, that had participated in their second phase-1 trial to treat EB, with INM-755, had completed treatment. The company had been developing INM-755 to treat EB and other dermatological diseases. The firm's clinical trial had been a vehicle-controlled, double-blind, and randomized phase 1 study to examine and assess the tolerability and safety of INM-755 cream, that had been applied and rubbed on epidermal wounds in healthy volunteers. This development is expected to have a positive impact on the market, during the forecast period. The rise and growth in investment and funding in the treatment of EB has made a significant impact in the market. Castle Creek Pharmaceutical has been making substantial developments in the market. The company had acquired Fibrocell Science and has become a major player in the development of treatments and cures for epidermolysis bullosa. The company has also been developing FCX-007, an investigational gene therapy, for the treatment of recessive dystrophic epidermolysis bullosa. FCX-007, the company's novel solutions, had been a cell-based therapy that is used to genetically modify the patient's dermal fibroblasts. These developments are expected to have a positive impact on the market, during the forecast period.

Segmentation:

  • By Treatment Type
  • Epidermolysis Bullosa Care
  • Drugs
  • Surgical Treatment
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Thailand
  • Taiwan
  • Indonesia
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Epidermolysis Bullosa Care and Treatment Market Analysis, By Treatment Type

  • 5.1. Introduction
  • 5.2. Epidermolysis Bullosa Care
  • 5.3. Drugs
  • 5.4. Surgical Treatment
  • 5.5. Others

6. Global Epidermolysis Bullosa Care and Treatment Market Analysis, by Ge-ography

  • 6.1. Introduction
  • 6.2. North America
    • 6.2.1. United States
    • 6.2.2. Canada
    • 6.2.3. Mexico
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
    • 6.3.3. Others
  • 6.4. Europe
    • 6.4.1. UK
    • 6.4.2. Germany
    • 6.4.3. France
    • 6.4.4. Italy
    • 6.4.5. Others
  • 6.5. The Middle East and Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. South Africa
    • 6.5.3. Others
  • 6.6. Asia Pacific
    • 6.6.1. Japan
    • 6.6.2. China
    • 6.6.3. India
    • 6.6.4. Thailand
    • 6.6.5. Taiwan
    • 6.6.6. Indonesia
    • 6.6.7. Others

7. Competitive Environment and Analysis

  • 7.1. Major Players and Strategy Analysis
  • 7.2. Emerging Players and Market Lucrativeness
  • 7.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 7.4. Vendor Competitiveness Matrix

8. Company Profiles

  • 8.1. Amryt Pharma PLC
  • 8.2. Abeona Therapeutics Inc.
  • 8.3. Ember Therapeutics
  • 8.4. TWi Pharmaceuticals Inc.
  • 8.5. Amicus Therapeutics
  • 8.6. InMed Pharmaceuticals Inc.
  • 8.7. RegeneRx Biopharmaceuticals Inc.
  • 8.8. Shionogi
  • 8.9. Castle Creek Pharmaceuticals
  • 8.10. Onconova Therapeutics